One research review notes that studies have consistently found that people with MS have markedly different gut microbiomes than those who don’t have the disease. The review’s authors believe ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The litigation revolves around US Patent No. 9,187,405, granted in 2015, which covers a dosing regimen for Gilenya (fingolimod) in relapsing-remitting MS. Novartis faces threat of early generic of ...

The win helps Gladiators top the table while it was Sultans' ninth defeat in ten matches PSL 2025 FAQs - what the six teams need to do in the final stretch What do the six PSL 2025 squads look ...

Heather du Plessis-Allan is a driving force at the centre of New Zealand’s biggest newsroom and number one radio station*.

The new centre in Crossgates will "make the campus an attractive option as a training facility within the UK".

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Objective To establish a rigorous, expert-led, evidence-based approach to the evaluation of licensed drugs for repurposing and testing in clinical trials of people with progressive multiple sclerosis ...